{"id":"W2616235887","doi":"10.1016/s0140-6736(17)30930-3","title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":197,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"Pfizer","keywords":"Medicine; Ulcerative colitis; Addressin; Placebo; Internal medicine; Clinical endpoint; Gastroenterology; Vedolizumab; Intention-to-treat analysis; Clinical trial; Surgery; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146529,0.0002926663,0.0007945845,0.00002896389,0.0007894816,0.0002847399,0.0008478313,0.0001698098,0.00005600832],"category_scores_gemma":[0.0004538786,0.0001994855,0.0004166783,0.00002110382,0.0002492517,0.00001664268,0.0001275225,0.0001386261,0.0000253807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001541658,"about_ca_system_score_gemma":0.0001799258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000126907,"about_ca_topic_score_gemma":0.00005997025,"domain_scores_codex":[0.9982752,0.000230887,0.0003883751,0.0004185705,0.0001807443,0.0005062163],"domain_scores_gemma":[0.997856,0.0001046907,0.0004130137,0.001335075,0.0001619781,0.0001292295],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9767207,0.0001688288,0.00006097252,0.00003474095,0.0004129891,0.00002852068,0.00007193237,0.00001594652,0.01481597,0.0003971688,0.006957625,0.0003146185],"study_design_scores_gemma":[0.9725761,0.0003558498,0.0005329648,0.00002155084,0.0002177965,0.000007287766,0.00002507048,0.0002320547,0.01474722,0.0001329566,0.01086301,0.0002881794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824445,0.0001064636,0.0008313647,0.0009099953,0.0007289029,0.008904235,0.0002975441,0.00003201285,0.005744928],"genre_scores_gemma":[0.9907655,0.0001096561,0.00009159059,0.0003976974,0.004596732,0.002010025,0.0003197766,0.00004098727,0.001668028],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008320955,"threshold_uncertainty_score":0.8134784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03194209354831734,"score_gpt":0.3493281749351027,"score_spread":0.3173860813867854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}